Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Morphosys AG Stock

Price
 
€117.30
0.6
0.510%
Target price
€122.00
09:49 / Tradegate WKN: 663200 / Name: MorphoSys / Stock / Biotechnologie & medizinische Forschung
Latest predictions
€126.00
04.12.19
buy
€102.00
21.10.19
buy
-
10.10.19
€120.00
04.01.19
buy
€110.50
27.02.18
buy
€128.90
16.07.17
buy
Your prediction

Morphosys AG Stock

Morphosys AG gained 0.510% compared to yesterday.
We see a rather positive sentiment for Morphosys AG with 6 Buy predictions and 1 Sell predictions.
As a result the target price of €122.00 shows a slightly positive potential of 4.007% compared to the current price of €117.30 for Morphosys AG.
Register To Post

Other discussions about Morphosys AG Stock

Trading Morphosys AG

Trading Morphosys AG

New thread

News

DGAP-News: Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure

DGAP-News: Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure

DGAP-Adhoc: Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis

DGAP-Adhoc: Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis

DGAP-News: MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice

DGAP-News: MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice

DGAP-News: Results for Bimagrumab in Obesity and Type 2 Diabetes  presented by MorphoSys's Partner : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSys's Partner

DGAP-News: Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSys's Partner

DGAP-News: MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting

DGAP-News: MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting

DGAP-News: MorphoSys AG Reports Third Quarter 2019 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG Reports Third Quarter 2019 Financial Results

DGAP-News: MorphoSys AG Reports Third Quarter 2019 Financial Results

DGAP-News: MorphoSys AG: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone

DGAP-News: MorphoSys AG: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone

DGAP-Adhoc: MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone

DGAP-Adhoc: MorphoSys AG: Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone

DGAP-News: MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped

DGAP-News: MorphoSys AG: MOR106 Clinical Development in Atopic Dermatitis Stopped

DGAP-Adhoc: MorphoSys AG: Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-Adhoc: MorphoSys AG: Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility

DGAP-Adhoc: MorphoSys AG: Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility

DGAP-News: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019

DGAP-News: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019

DGAP-News: MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China

DGAP-News: MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China